PDF herunterladen
Horm Metab Res 2021; 53(08): 504-511
DOI: 10.1055/a-1499-7718
Endocrine Care

Anti-Müllerian Hormone Accelerates Pathological Process of Insulin Resistance in Polycystic Ovary Syndrome Patients

Xiang-Juan Li‡
1   Department of Obstetrics and Gynecology, Hangzhou Women's Hospital, Hangzhou, China
,
Hui Wang‡
2   Department of Obstetrics and Gynecology, Maternal and Child Health Hospital of Songjiang District, Shanghai, China
,
Dan-Yang Lu
3   Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China
,
Tian-Tian Yu
3   Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China
,
Kamran Ullah
4   Department of Biological Sciences (Zoology), University of Lakki Marwat, Khyber Pakhtunkhwa, Pakistan
,
Xin-Yan Shi
1   Department of Obstetrics and Gynecology, Hangzhou Women's Hospital, Hangzhou, China
,
Yong-Hai Shen
1   Department of Obstetrics and Gynecology, Hangzhou Women's Hospital, Hangzhou, China
,
Xiao-Yang Fei
1   Department of Obstetrics and Gynecology, Hangzhou Women's Hospital, Hangzhou, China
,
Zhen-Yun Lin
1   Department of Obstetrics and Gynecology, Hangzhou Women's Hospital, Hangzhou, China
,
He-Feng Huang
3   Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China
5   The Key Laboratory of Reproductive Genetics, Ministry of Education (Zhejiang University), Hangzhou, China.
,
Xian-Hua Lin
5   The Key Laboratory of Reproductive Genetics, Ministry of Education (Zhejiang University), Hangzhou, China.
› Institutsangaben Funding Information This study was funded by the National Key Research and Development Program of China (No. 2018YFC1005001), the National Natural Science Foundation of China (No. 82071730) and Research Grant from Shanghai Hospital Development Center (No. SHDC12019X17).
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Abstract

Insulin resistance (IR) is one of the most common features of polycystic ovary syndrome (PCOS), which is related to obesity. Whether increased anti-Müllerian hormone (AMH) levels in PCOS are involved in the pathogenesis of insulin resistance remains unclear. We investigated serum levels of leptin and AMH along with basic clinical and metabolic parameters in 114 PCOS patients and 181 non-PCOS women. PCOS patients presented higher fasting blood glucose, insulin concentrations and Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) in addition to body mass index (BMI), lipids profiles and hormone levels. HOMA-IR showed a positive correlation with BMI, AMH, leptin, and low-density lipoprotein-cholesterol (LDL-c) levels. Interestingly, AMH is strongly positively correlated with HOMA-IR and insulin concentrations for 1st and 2nd hours of glucose treatment after fasting. Among PCOS women with BMI≥25 kg/m2, high AMH level group showed an increased HOMA-IR when compared to normal AMH level. However, among PCOS women with normal BMI, women with high AMH presented an elevated fasting insulin levels but not HOMA-IR when compared to normal AMH group. In vitro treatment of isolated islet cells with high concentration of leptin (200 ng/ml) or high leptin plus high concentration of AMH (1 ng/ml) significantly enhanced insulin secretion. Importantly, co-treatment of AMH plus leptin upregulates the expression of pro-apoptotic proteins, such as Bax, caspase-3, and caspase-8 after incubating with a high level of glucose. These results suggest that AMH may involve in the pathological process of pancreatic β-cells in obese PCOS women.

Key words

anti-Mullerian hormone - insulin resistance - apoptosis - pancreatic islet cells

Supplementary Material



Publikationsverlauf

Eingereicht: 05. Februar 2021

Angenommen nach Revision: 26. April 2021

Artikel online veröffentlicht:
12. August 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Dapas M, Lin FTJ, Nadkarni GN. et al. Distinct subtypes of polycystic ovary syndrome with novel genetic associations: An unsupervised, phenotypic clustering analysis. PLoS Med 2020; 17: e1003132
    CrossrefPubMedGoogle Scholar
  • 2 Rotterdam EA-SPcwg. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19: 41-47
    CrossrefPubMedGoogle Scholar
  • 3 Dunaif A, Segal KR, Futterweit W. et al. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989; 38: 1165-1174
    CrossrefPubMedGoogle Scholar
  • 4 Weenen C, Laven JS, Von Bergh AR. et al. Anti-Mullerian hormone expression pattern in the human ovary: Potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod 2004; 10: 77-83
    CrossrefPubMedGoogle Scholar
  • 5 Pankhurst MW. A putative role for anti-Müllerian hormone (AMH) in optimising ovarian reserve expenditure. J Endocrinol 2017; 233: R1-R13
    CrossrefPubMedGoogle Scholar
  • 6 Khan HL, Bhatti S, Suhail S. et al. Antral follicle count (AFC) and serum anti-Müllerian hormone (AMH) are the predictors of natural fecundability have similar trends irrespective of fertility status and menstrual characteristics among fertile and infertile women below the age of 40 years. Reprod Biol Endocrinol 2019; 17: 20
    CrossrefPubMedGoogle Scholar
  • 7 Dewailly D, Andersen CY, Balen A. et al. The physiology and clinical utility of anti-Mullerian hormone in women. Hum Reprod Update 2014; 20: 370-385
    CrossrefPubMedGoogle Scholar
  • 8 Visser JA, Themmen AP. Anti-Mullerian hormone and folliculogenesis. Mol Cell Endocrinol 2005; 234: 81-86
    CrossrefPubMedGoogle Scholar
  • 9 Durlinger AL, Gruijters MJ, Kramer P. et al. Anti-Mullerian hormone attenuates the effects of FSH on follicle development in the mouse ovary. Endocrinology 2001; 142: 4891-4899
    CrossrefPubMedGoogle Scholar
  • 10 Allagnat F, Fukaya M, Nogueira TC. et al. C/EBP homologous protein contributes to cytokine-induced pro-inflammatory responses and apoptosis in beta-cells. Cell Death Differ 2012; 19: 1836-1846
    CrossrefPubMedGoogle Scholar
  • 11 Liu S, Du F, Li X. et al. Effects and underlying mechanisms of irisin on the proliferation and apoptosis of pancreatic beta cells. PLoS One 2017; 12: e0175498
    CrossrefPubMedGoogle Scholar
  • 12 Gillman MW. A life-course approach to obesity.In Kuh D, Ben-Shlomo Y, Eds A Life Course Approach to Chronic Disease Epidemiology. Oxford: Oxford University Press 2004: 189–217
  • 13 Matthews DR, Hosker JP, Rudenski AS. et al. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419
    CrossrefPubMedGoogle Scholar
  • 14 Martinez SC, Tanabe K, Cras-Meneur C. et al. Inhibition of Foxo1 protects pancreatic islet beta-cells against fatty acid and endoplasmic reticulum stress-induced apoptosis. Diabetes 2008; 57: 846-859
    CrossrefPubMedGoogle Scholar
  • 15 Ding GL, Wang FF, Shu J. et al. Transgenerational glucose intolerance with Igf2/H19 epigenetic alterations in mouse islet induced by intrauterine hyperglycemia. Diabetes 2012; 61: 1133-1142
    CrossrefPubMedGoogle Scholar
  • 16 He RH, Sheng JZ, Luo Q. et al. Aquaporin-2 expression in human endometrium correlates with serum ovarian steroid hormones. Life Sci 2006; 79: 423-429
    CrossrefPubMedGoogle Scholar
  • 17 Shanik MH, Xu Y, Skrha J. et al. Insulin resistance and hyperinsulinemia: is hyperinsulinemia the cart or the horse?. Diabetes Care 2008; 31 (Suppl. 02) S262-S268
    CrossrefPubMedGoogle Scholar
  • 18 Stepto NK, Cassar S, Joham AE. et al. Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp. Hum Reprod 2013; 28: 777-784
    CrossrefPubMedGoogle Scholar
  • 19 Azziz R, Ehrmann DA, Legro RS. et al. Troglitazone decreases adrenal androgen levels in women with polycystic ovary syndrome. Fertil Steril 2003; 79: 932-937
    CrossrefPubMedGoogle Scholar
  • 20 Chao KC, Ho CH, Shyong WY. et al. Anti-Mullerian hormone serum level as a predictive marker of ovarian function in Taiwanese women. J Chin Med Assoc 2012; 75: 70-74
    CrossrefPubMedGoogle Scholar
  • 21 Cui Y, Shi Y, Cui L. et al. Age-specific serum antimullerian hormone levels in women with and without polycystic ovary syndrome. Fertil Steril 2014; 102: 230-236 e232
    CrossrefPubMedGoogle Scholar
  • 22 Verdiesen RMG, Onland-Moret NC, van Gils CH. et al. Anti-Müllerian hormone levels and risk of type 2 diabetes in women. Diabetologia 2021; 64: 375-384
    CrossrefPubMedGoogle Scholar
  • 23 Tokmak A, Kokanali D, Timur H. et al. Association between anti-Mullerian hormone and insulin resistance in non-obese adolescent females with polycystic ovary syndrome. Gynecol Endocrinol 2016; 32: 926-930
    CrossrefPubMedGoogle Scholar
  • 24 Carmina E, Orio F, Palomba S. et al. Ovarian size and blood flow in women with polycystic ovary syndrome and their correlations with endocrine parameters. Fertil Steril 2005; 84: 413-419
    CrossrefPubMedGoogle Scholar
  • 25 Fonseca HP, Brondi RS, Piovesan FX. et al. Anti-Mullerian hormone and insulin resistance in polycystic ovary syndrome. Gynecol Endocrinol 2014; 30: 667-670
    CrossrefPubMedGoogle Scholar
  • 26 Caglar GS, Kahyaoglu I, Pabuccu R. et al. Anti-Mullerian hormone and insulin resistance in classic phenotype lean PCOS. Arch Gynecol Obstet 2013; 288: 905-910
    CrossrefPubMedGoogle Scholar
  • 27 Tian X, Ruan X, Mueck AO. et al. Serum anti-Mullerian hormone and insulin resistance in the main phenotypes of non-obese polycystic ovarian syndrome women in China. Gynecol Endocrinol 2014; 30: 836-839
    CrossrefPubMedGoogle Scholar
  • 28 La Marca A, Orvieto R, Giulini S. et al. Mullerian-inhibiting substance in women with polycystic ovary syndrome: Relationship with hormonal and metabolic characteristics. Fertil Steril 2004; 82: 970-972
    CrossrefPubMedGoogle Scholar
  • 29 Pache TD, de Jong FH, Hop WC. et al. Association between ovarian changes assessed by transvaginal sonography and clinical and endocrine signs of the polycystic ovary syndrome. Fertil Steril 1993; 59: 544-549
    CrossrefPubMedGoogle Scholar
  • 30 Dahan MH, Reaven G. Relationship among obesity, insulin resistance, and hyperinsulinemia in the polycystic ovary syndrome. Endocrine 2019; 64: 685-689
    CrossrefPubMedGoogle Scholar
  • 31 de Kat AC, Verschuren WM, Eijkemans MJ. et al. Anti-mullerian hormone trajectories are associated with cardiovascular disease in women: Results from the doetinchem cohort study. Circulation 2017; 135: 556-565
    CrossrefPubMedGoogle Scholar
  • 32 McLennan IS, Pankhurst MW. Anti-Mullerian hormone is a gonadal cytokine with two circulating forms and cryptic actions. J Endocrinol 2015; 226: R45-R57
    CrossrefPubMedGoogle Scholar
  • 33 Prapa E, Vasilaki A, Dafopoulos K. et al. Effect of Anti-Mullerian hormone (AMH) and bone morphogenetic protein 15 (BMP-15) on steroidogenesis in primary-cultured human luteinizing granulosa cells through Smad5 signalling. J Assist Reprod Genet 2015; 32: 1079-1088
    CrossrefPubMedGoogle Scholar
  • 34 Carlsson IB, Scott JE, Visser JA. et al. Anti-Mullerian hormone inhibits initiation of growth of human primordial ovarian follicles in vitro. Hum Reprod 2006; 21: 2223-2227
    CrossrefPubMedGoogle Scholar
  • 35 Leahy JL. Pathogenesis of type 2 diabetes mellitus. Arch Med Res 2005; 36: 197-209
    CrossrefPubMedGoogle Scholar
  • 36 Butler AE, Janson J, Bonner-Weir S. et al. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003; 52: 102-110
    CrossrefPubMedGoogle Scholar
  • 37 Emamaullee JA, Shapiro AM. Interventional strategies to prevent beta-cell apoptosis in islet transplantation. Diabetes 2006; 55: 1907-1914
    CrossrefPubMedGoogle Scholar
  • 38 Nakano M, Matsumoto I, Sawada T. et al. Caspase-3 inhibitor prevents apoptosis of human islets immediately after isolation and improves islet graft function. Pancreas 2004; 29: 104-109
    CrossrefPubMedGoogle Scholar
  • 39 Cheng G, Zhu L, Mahato RI. Caspase-3 gene silencing for inhibiting apoptosis in insulinoma cells and human islets. Mol Pharm 2008; 5: 1093-1102
    CrossrefPubMedGoogle Scholar
  • 40 Scarfo L, Ghia P. Reprogramming cell death: BCL2 family inhibition in hematological malignancies. Immunol Lett 2013; 155: 36-39
    CrossrefPubMedGoogle Scholar
  • 41 Yuan L, Li Y, Li G. et al. Ang(1-7) treatment attenuates beta-cell dysfunction by improving pancreatic microcirculation in a rat model of Type 2 diabetes. J Endocrinol Invest 2013; 36: 931-937
    PubMedGoogle Scholar
  • 42 Gross A, Yin XM, Wang K. et al. Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-R1/Fas death. J Biol Chem 1999; 274: 1156-1163
    CrossrefPubMedGoogle Scholar